
Brian Williams

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3915694/publications.pdf Version: 2024-02-01



RDIAN WILLIAMS

#	Article	IF	CITATIONS
1	The scale and dynamics of COVID-19 epidemics across Europe. Royal Society Open Science, 2020, 7, 201726.	2.4	21
2	Epidemiological metrics and benchmarks for a transition in the HIV epidemic. PLoS Medicine, 2018, 15, e1002678.	8.4	59
3	A signature for biological heterogeneity in susceptibility to HIV infection?. Infectious Disease Modelling, 2018, 3, 139-144.	1.9	3
4	Modelling challenges in context: Lessons from malaria, HIV, and tuberculosis. Epidemics, 2015, 10, 102-107.	3.0	16
5	Mass treatment to eliminate tuberculosis from an island population. International Journal of Tuberculosis and Lung Disease, 2014, 18, 899-904.	1.2	8
6	HIV Treatment as Prevention: Debate and Commentary—Will Early Infection Compromise Treatment-as-Prevention Strategies?. PLoS Medicine, 2012, 9, e1001232.	8.4	88
7	Nutrition, Diabetes and Tuberculosis in the Epidemiological Transition. PLoS ONE, 2011, 6, e21161.	2.5	57
8	Highly active antiretroviral treatment for the prevention of HIV transmission. Journal of the International AIDS Society, 2010, 13, 1-1.	3.0	285
9	Antiretroviral therapy for tuberculosis control in nine African countries. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19485-19489.	7.1	89
10	A consistent log-linear relationship between tuberculosis incidence and body mass index. International Journal of Epidemiology, 2010, 39, 149-155.	1.9	323
11	The Population Dynamics and Control of Tuberculosis. Science, 2010, 328, 856-861.	12.6	559
12	Slow Elimination of Multidrug-Resistant Tuberculosis. Science Translational Medicine, 2009, 1, 3ra8.	12.4	17
13	Trends in tuberculosis incidence and their determinants in 134 countries. Bulletin of the World Health Organization, 2009, 87, 683-691.	3.3	282
14	Modelling local and global effects on the risk of contracting Tuberculosis using stochastic Markov-chain models. Mathematical Biosciences, 2009, 218, 98-104.	1.9	3
15	Incongruent HIV and tuberculosis co-dynamics in Kenya: Interacting epidemics monitor each other. Epidemics, 2009, 1, 14-20.	3.0	10
16	Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, The, 2009, 373, 48-57.	13.7	1,720
17	Universal voluntary HIV testing and immediate antiretroviral therapy – Authors' reply. Lancet, The, 2009, 373, 1080-1081.	13.7	19
18	Clinical Prognostic Value of RNA Viral Load and CD4 Cell Counts during Untreated HIV-1 Infection—A Quantitative Review. PLoS ONE, 2009, 4, e5950.	2.5	55

BRIAN WILLIAMS

#	ARTICLE	IF	CITATIONS
19	New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bulletin of the World Health Organization, 2009, 87, 186-192.	3.3	14
20	Eliminating human tuberculosis in the twenty-first century. Journal of the Royal Society Interface, 2008, 5, 653-662.	3.4	135
21	Reply to Lawn and Wood. Journal of Infectious Diseases, 2007, 195, 1079-1079.	4.0	0
22	Diabetes and the risk of tuberculosis: a neglected threat to public health?. Chronic Illness, 2007, 3, 228-245.	1.5	181
23	Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infectious Diseases, The, 2006, 6, 483-495.	9.1	132
24	The Potential Impact of Male Circumcision on HIV in Sub-Saharan Africa. PLoS Medicine, 2006, 3, e262.	8.4	290
25	Tuberculosis control in the era of HIV. Nature Reviews Immunology, 2005, 5, 819-826.	22.7	216
26	What is the limit to case detection under the DOTS strategy for tuberculosis control?. Tuberculosis, 2003, 83, 35-43.	1.9	44
27	Effects of Human Immunodeficiency Virus Infection on Recurrence of Tuberculosis after Rifampin-Based Treatment: An Analytical Review. Clinical Infectious Diseases, 2003, 37, 101-112.	5.8	153
28	Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infectious Diseases, The, 2003, 3, 349-358.	9.1	206
29	Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS. Science, 2003, 301, 1535-1537.	12.6	214
30	Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis. Science, 2002, 295, 2042-2046.	12.6	289
31	Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infectious Diseases, The, 2002, 2, 25-32.	9.1	735
32	Criteria for the control of drug-resistant tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8180-8185.	7.1	209
33	Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet, The, 1998, 352, 1886-1891.	13.7	393
34	Infectious disease persistence when transmission varies seasonally. Mathematical Biosciences, 1997, 145, 77-88.	1.9	34
35	Measles vaccination policy. Epidemiology and Infection, 1995, 115, 603-621.	2.1	31